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Background: The FSH starting dose is usually chosen according to women’s age, anamnesis, clinical criteria and
markers of ovarian reserve. Currently used markers include antral follicle count (AFC), which is considered to have a
very high performance in predicting ovarian response to FSH. The objective of the present study to elaborate a
nomogram based on AFC for the calculation of the appropriate FSH starting dose in IVF cycles.
Methods: This is a retrospective study performed at the Mother-Infant Department of Modena University Hospital.
IVF patients (n=505) were subjected to blood sampling and transvaginal ultrasound for measurement of serum
day3 FSH, estradiol and AFC. The variables predictive of the number of retrieved oocytes were assessed by
backwards stepwise multiple regression. The variables reaching the statistical significance were then used in the
calculation for the final predictive model.
Results: A model based on age, AFC and FSH was able to accurately predict the ovarian sensitivity and accounted
for 30% of the variability of ovarian response to FSH. An FSH dosage nomogram was constructed and overall it
predicts a starting dose lower than 225 IU in 50.2% and 18.1% of patients younger and older than 35 years,
respectively.
Conclusions: The daily FSH dose may be calculated on the basis of age and two markers of ovarian reserve,
namely AFC and FSH, with the last two variables being the most significant predictors. The nomogram seems easily
applicable during the daily clinical practice.
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The main aspect of the “individualization” in IVF cycles
is to offer every single patient the best therapy tailored
on her own characteristics thus allowing a high chance
of success and of course minimizing the risks deriving
from ovarian stimulation. Choosing different doses of
gonadotrophins for different patients is the most import-
ant clinical decision in the personalization of therapy.
Although exogenous FSH has been used for decades,
and millions of cycles have been performed worldwide,
criteria to select the proper starting FSH dose have not
yet been completely identified.* Correspondence: antlamarca@libero.it
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reproduction in any medium, provided the orUsually clinicians choose the FSH starting dose
according to anamnesis and clinical criteria, the most
important being the outcome of previous IVF cycles. If
no previous cycles have been performed, the choice will
be based on criteria as women's age, BMI and markers
of ovarian reserve [1,2].
Currently used markers of ovarian reserve include FSH,
AMH and antral follicle count (AFC), with the last two
markers having the best performance in predicting ovarian
response to exogenous FSH [3-5]. Ovarian antral follicles
larger than 2 mm are extremely sensitive and responsive
to FSH and are defined as "recruitable". They can be visua-
lized and measured with transvaginal ultrasound and the
total number of 2–10 mm follicles in both the ovaries
represents the AFC [6,7]. Hence the AFC estimates with a
very good accuracy the extent of the pool of follicles on
which the exogenous FSH will act.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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good correlation between AFC and ovarian response in
IVF programs [8,9]. AFC is also correlated to the onset of
menopausal transition [10] thus indicating the close rela-
tionship with the quantitative aspect of ovarian reserve.
AMH and AFC are nowadays considered two markers
with similar diagnostic performance [4,8]. Indeed AMH
and AFC actually measure the same thing: the pool of
recruitable follicles. While AMH appears to have im-
portant advantages over AFC, as the lowest intra- and
inter-menstrual cycle variability and the operator-inde-
pendence, the great advantage of the AFC is the possibil-
ity of its measurement at the same moment in which
clinicians examine the patient; hence, with great cer-
tainty we can assert that AFC will continue to be a
widely used marker of ovarian reserve.
Although tailored therapy based on markers of ovarian
reserve appears to be an agreed upon approach by most,
studies suggesting how to determine individualized ther-
apy compared to ‘one size fits all’ are scarce. On the use
and efficacy of the single value of AMH in tailored treat-
ment, two studies have been published [11,12]. In both
studies the FSH starting dose decreased with increasing
basal serum AMH and both studies indicated that the
treatment strategy based on AMH may lead to a reduction
of both excessive responses and cancelled cycles [11,12].
Recently a more complete and easy to use nomogram has
been elaborated in order to calculate the most appropriate
FSH starting dose in IVF cycles [13]. The nomogram is
based on patient’s age, serum day3 FSH and AMH and
may be the basis for the individualization of the FSH dose
for all patients in those centers using AMH to investigate
ovarian reserve.
While an important role for AFC in the identification
of the extremes of ovarian response has been proven
[8,9], its role in the individualization of the therapeutic
strategy such as the choice of the FSH starting dose still
need to be clarified. For this reason, we wished to inves-
tigate whether it is possible to elaborate a nomogram
based on patients characteristics and AFC, able to sug-
gest the appropriate starting dose of exogenous gonado-
trophin in IVF cycles, aiming to possibly reduce the
extremes of ovarian response.
Methods
We retrospectively analyzed the database containing clin-
ical and laboratory information on IVF treatment cycles
carried out at the Mother-Infant Department of University
Hospital since the introduction of the routinely use and
registration of antral follicle count. These data have been
collected and recorded in the registered database in our
fertility centre in Modena, Italy. Cycles were selected for
analysis if all the following inclusion criteria were satisfied:
1. first IVF/ICSI attempt, 2. regular menstrual cycle (25–35days), 3. female age ≤ 40, 4. treatment with a long GnRH
agonist protocol, 5. starting FSH dose of 225 IU per day for
the first 5–6 days, 6. complete patient records on anamnes-
tic, clinical, IVF cycle characteristics, 7. serum day3 FSH,
estradiol and day3 AFC measured not more than 3 months
before the IVF cycle. All patients had been trying to con-
ceive for at least 12 months and had undergone a fertility
workup. Clinical exclusion criteria were: irregular cycles,
evidence of PCO status, previous ovarian surgery, endo-
metriosis, basal day3 FSH >15IU/L, presence of ovarian
cysts, history of PID, use of hormonal contraception in the
previous 3 months, any known metabolic or endocrino-
logical disease.
Of the eligible patients five hundred and five were
selected while more than fifteen hundreds women were
excluded on the basis of inclusion and exclusion criteria.
The long GnRH agonist protocol was based on the ad-
ministration of daily leuprorelin (Enantone die, Takeda,
Italy) on day 21 of the previous luteal phase of the stimu-
lation cycle. Recombinant FSH at a dose of 225 IU/day
(Gonal F, Merck Serono, Italy) subcutaneously was com-
menced when pituitary desensitization was achieved (~14
days after the initiation of GnRH agonists), as evidenced
by the absence of ovarian follicles >10 mm and endomet-
rial thickness <4 mm on transvaginal ultrasound examin-
ation, and then the dose was adjusted on day 6–7 of
stimulation according to the ovarian response. When at
least three follicles reached ≥ 18 mm, 10000 IU of hCG
(Gonasi, IBSA, Italy) were administrated intramuscularly
and 34–36 hours later follicles were aspirated under pa-
tient sedation. Cycle cancellation occurred because of ab-
sent response when no follicle growth was evident
following at least one week of FSH administration. Cycle
cancellation for excessive response was applied in the oc-
currence of ≥20 follicles (total number) ≥11 mm in mean
diameter and/or E2 level ≥4,000 pg/mL on the day on
which final oocyte maturation induction was scheduled.
All patients gave written informed consent at the time of
the IVF cycle for both the procedure and for recording
and using laboratory and clinical data related to their
medical history for clinical research purpose.
Ultrasound and hormone assay
Blood samples were taken between 8:00 a.m and 12:00 p.m.
from the cubital vein, in the early follicular phase (day 3)
prior to any IVF-related drug administration. Serum FSH
was measured by a chemiluminescent assay (ADVIA Cen-
taur, Siemens Healthcare Diagnostics, Italy). The sensitivity
of the assay was 0.1IU/L; intra- and inter-assay coefficients
of variation were 2.7 and 3.1%, respectively. Estradiol was
measured by a competitive chemiluminescent assay
(ADVIA Centaur Siemenes Healthcare Diagnostics, Italy).
The sensitivity was 10 pg/ml and the intra- and inter-assay
coefficients of variations were 3.1% and 5%, respectively.
Table 1 Patients and IVF cycles characteristics
Variables n=505
Age, years (M±SD) 34.1±3.9
BMI (kg/m2) 21.86±2.7
Smokers (%) 17
Non Smokers (%) 83








Total day3 AFC (M±SD) 9.6±5.8
day 3 FSH, IU/L ( M±SD) 6.3±3.4
Duration of stimulation, days (M±SD) 11.1±2.1
Total FSH administered, IU (M±SD) 2500±1050
Number of retrieved oocytes per patientb, (M±SD; median) 9.2±6.4; 8.7
a some couples had more than one cause of infertility.
b patients reaching pick up=468. 16 patients were cancelled because of absent
response, 21 patients were cancelled because of high risk of OHSS.
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same day of blood sample by using the 6.5 MHz vaginal
probe on a Esaote AU4 Idea (Esaote, Milan, Italy).
Examination of the ovary was established by scanning
from the outer to the inner margin. All 2–10 mm folli-
cles in site were counted in each ovary. Follicular size is
measured using the internal diameters of the area. The
mean of two perpendicular measurements was assumed
to be the follicular size. The sum of counts in both ovar-
ies produced the AFC.
Statistical analyses
Cycles cancelled for absent response were assigned a
number of retrieved oocytes of zero. Cycles cancelled for
excessive response were arbitrarily assigned a number ofTable 2 Predictors of number of retrieved oocytes in univaria
Variable Univariate
Regresssion coefficient Standard Error
Age −0,28116 0,05076 <0
FSH −0,32630 0,06085 <0




Basal estradiol −0,00664 0,00503
Smoking status −0.00051 0.00008retrieved oocytes corresponding to the 90° centile of the
number of retrieved oocytes in the overall population (90°
centile=18 oocytes). The variables predictive of the number
of retrieved oocytes were assessed by backwards stepwise
multiple regression. Backward selection of parameters was
applied, using Wald P<0.05 for entry and P>0.1 for re-
moval. The variables reaching the statistical significance in
multivariate regression analysis were then used in the cal-
culation for the final model elaborated in order to deter-
mine the dose of gonadotropin needed to achieved the
desired response. Regression coefficients for each variables
were incorporated in an algorithm were the dependent
variable was the dose of FSH needed to obtain the desired
response. In this study the desired response was the me-
dian number of oocytes retrieved in the overall female
population (nine oocytes). As already reported elsewhere
[13] the increase in the number of cycles with an oocyte
yield close to the median value may be followed by a re-
duction in the number of cycles with an extreme ovarian
response. Statistical analysis was performed using the soft-
ware Stata 10 (StataCorp, Texas, USA).
Results
In total 505 started cycles were available for statistical
analysis. Patients and IVF cycles characteristics are
reported in Table 1. Mean (±SD) age of patients was
34.1 (±3.9) yrs (range: 22–40). The 92.6% (n=468) of
women reached the oocyte pick-up. Sixteen cycles were
cancelled because of absent follicle growth and 21 were
cancelled because of excessive ovarian response. Mean
(±SD) number of retrieved oocytes was 9.2 (±6.4).
Results of univariate and multivariate regression ana-
lyses with the number of oocytes as a dependent variable
are shown in Table 2. The independent variables were:
age, height, weight, BMI, smoking status, day3 FSH, es-
tradiol and AFC. The univariate regression analysis
showed that the number of retrieved oocytes was signifi-
cantly predicted by age, BMI, smoking status, d3FSH
and AFC, however in the multivariate regression analysis
the statistical significance was reached only for age,te and multivariate backward regression analysis
Multivariate
p Regresssion coefficient Standard Error p
.0001 −0,08732 0,05046 0.02
.0001 −0,22924 0,05726 0.0001
.0001 0,35517 0,03538 <0.0001
0.01 −0,001 0,00005 ns
ns −0,01 0,003 ns
0.09 0,03 0,02 ns
ns −0,004 0,005 ns
0.01 −0.0005 0.00003 ns
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regression analysis accounts for 30% of the variability of
ovarian sensitivity (R2=0.31; R2-adjusted: 0.3). According
to the model, for women of similar age, the number of
retrieved oocytes will be reduced with decreasing of
AFC and increasing of day 3 serum FSH. The most sig-
nificant predictors of ovarian sensitivity were FSH
(P=0.0001) and AFC (P<0.0001).
The model shown in Table 2 was then used to elaborate
a dosage normogram which could be easily adopted inFigure 1 The nomogram for the calculation of the FSH starting dose
year old woman with AFC=16 and d3FSH = 4IU/L, the FSH starting dose is
dosage dial based on doses of FSH of 12.5 IU, on the right side of the FSH
is reported (150 IU /day for the example).daily clinical practice (Figure 1). The FSH dosage normo-
gram was constructed after setting the desirable number
of retrieved oocytes as nine. The optimal number of
oocytes was set as nine since it is the mean (and median)
number of retrieved oocytes in the present study.
A simplified model based only on age and AFC was
developed (Figure 2). Of course this model has a lower
accuracy than the three-variables model (R2-adjusted:
0.25 vs 0.3, respectively). The three-variables-nomogram
reported in Figure 1 was then applied on the samebased on age, AFC and serum day 3FSH. In the example, for a 30
152 IU per day. Since the new FSH delivery system will have the
starting dose column, the FSH dose as selected for the delivery system
Figure 2 The nomogram for the calculation of the FSH starting dose based on age and AFC. In the example, for a 30 year old woman
with AFC=16 , the FSH starting dose is 161.5 IU per day. Since the new FSH delivery system will have the dosage dial based on doses of FSH of
12.5 IU, on the right side of the FSH starting dose column, the FSH dose as selected for the delivery system is reported (150 IU /day for
the example).
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the model predicted a FSH starting dose lower than 225
IU in 30% of patients. Interestingly, this percentage was
higher for younger patients (≤ 35 yrs: 50.2%) than for
older patients (>35 yrs: 18.1%) (Figure 3).
Discussion
Results of the present study confirm that ovarian response
to a standard dose of FSH mainly depends on ovarian re-
serve. Indeed, in the present study the number of retrieved
oocytes is significantly predicted by age and two markers
of ovarian reserve namely AFC and FSH, with the last two
variables being the most significant predictors.The multiple follicular growth in cycles of assisted
reproduction is effected using exogenous FSH, leading
to supranormal circulating concentrations and recruit-
ment of all follicles whose FSH sensitivity threshold is
exceeded [14,15]. When exogenous FSH is administered,
the number of follicles induced to grow largely depends
upon the number of follicles and their FSH sensitivity
[16,17]. That is the main reason why an algorithm in-
cluding AFC and serum d3FSH may correctly predict
the number of retrieved oocytes following ovarian
stimulation.
The prediction of oocyte yield is the basis for tailoring












<225           <150     150-187.5  187.5-224                                     <225           <150     150-187.5  187.5-224
>35 yrs ≤35 yrs
FSH starting dose (IU/day)
Figure 3 The FSH starting dose for patients included in the study was calculated by the nomogram incorporating age, AFC and FSH.
Overall the model predicts a dose lower than 225 IU of FSH in 50.2% of patients ≤35 yrs (12.8%, 16.9% and 20.5% of patients had a predicted
daily dose of <150, 150–187.5 and 187.5-225 IU, respectively). The percentage of women >35 yrs with a predicted dose lower than 225 IU was
18.1% (3.2%, 7.8% and 7.1% of women had a predicted daily dose of <150, 150–187.5 and 187.5-225 IU, respectively).
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be secondary to an accurate prediction of oocyte yield
following maximal ovarian stimulation. If the predicted
oocyte yield is suggestive for excessive ovarian response
the starting dose of FSH should be lower than the one
leading to the maximal stimulation. For this reason,
some authors examined and tested complex models
based on multiple phenotypic, ultrasound derived and
biochemical indexes to dictate starting doses of exogen-
ous gonadotrophins in IVF cycles [18,19].
A first prospective study showed that the combination
of age, antral follicle count (AFC), ovarian volume, Dop-
pler ovarian score and smoking status may allow clinicians
to choose the appropriate FSH dose in IVF cycles [19]. In
a second study the proposed model was based on age,
body mass index (BMI), serum day 3 FSH (d3FSH) and
AFC [18]. Both models were then validated in successive
prospective trials, demonstrating that the application of an
individualized versus standard FSH dose was associated
with a reduced cancellation rate for abnormal ovarian re-
sponse, reduced need of adjusting the dose during treat-
ment and increased occurrence of an adequate ovarian
response [20,21]. Unfortunately both the published nomo-
grams may not be used by clinicians in their practice since
the nomogram by Popovic-Todorovic [19] was based on a
Doppler score of ovarian stromal blood flow and testoster-
one levels, which are not commonly measured in the clin-
ical practice, whereas the model created by Howles [18]
has never been publicly disclosed.In the present study ovarian response is significantly pre-
dicted by age, serum FSH and AFC and this model may
permit the construction of an FSH dosage nomogram. The
nomogram (Figure 1) was constructed after setting the de-
sirable number of retrieved oocytes as nine. As already said,
the hypothesis was that stimulating the ovaries wishing to
obtain a number of oocytes close to the median in the
whole population leads to a narrow distribution of ovarian
responses around that value. This would imply that fewer
women would exhibit an inadequate response (i.e. poor or
excessive response). This methodology has been success-
fully used in previously published models [13,18,19]. More-
over nine is the middle point of the appropriate ovarian
response when defined as the retrieval of 5 to 14 oocytes
[19,22] and the middlepoint between the cut-off values usu-
ally used to define “poor response” (<4 oocytes) [23] and
“excessive ovarian response” (>15) [8,24-26].
The need of individualizing doses of FSH in patients
derives from the assumption that variability in the func-
tional ovarian reserve (the pool of recruitable follicles) is
very wide; therefore a standard fixed dose of FSH may not
be suitable for all women [27]. Indeed several observations
[19,21,22] indicate that 150 IU of FSH is the optimal dose
for part of the studied patients, with others requiring
higher doses of FSH in order to reach the optimal stimula-
tion. On the other hand a large proportion of OHSS cases
are preventable by reducing the FSH starting dose in
women at risk of excessive ovarian response, namely those
with a large pool of recruitable follicles.
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the starting dose of FSH in IVF cycles should be indivi-
dualized. In the present study we clearly demonstrated
that the FSH daily dose may be calculated on the basis of
the age of patients and of two markers of ovarian reserve,
namely AFC and FSH, with the last two variables being
the most significant predictors. The model based on AFC
resembles a previously published model based on AMH
[13]. The two models have the same accuracy in predict-
ing ovarian response to gonadotropins and this is not sur-
prising since a linear strong relationship exists between
AFC and AMH [4,7]. The strong correlation between the
two markers reflects the fact that the same ovarian folli-
cles which are seen on ultrasound secrete AMH. One rele-
vant benefit of AFC is the possibility of its measurement
at the same moment in which clinicians examine the pa-
tient hence we developed a second simplified model based
only on age and AFC (Figure 2). As expected the two vari-
ables model is less accurate than the one incorporating
age, FSH and AFC, but being independent of the blood
sample makes it highly interesting for clinicians.
When the nomogram we developed was tested in the
same population used to elaborate the model (Figure 3),
it predicted a dose lower than 150 IU in 8% of patients,
a dose between 150 and 187.5 IU in 11.5% of patients,
or between 187.5 and 225 IU in 10.5% of patients. In
women ≤ 35 years the calculated FSH starting dose was
lower than 225 IU in 50.2% of patients while it was
lower than 225 IU only in 18.1% of women > 35 years.
Before clinicians can adopt the model into routine clin-
ical practice, the accuracy of the model should be inde-
pendently evaluated in a population different from the
one on which the model was elaborated. External valid-
ation is therefore crucial to assess the generalizability of
our model to other populations.
Conclusions
We have demonstrated that ovarian response to COS
depends on patient’s age and on the pool of recruitable
follicles and follicular sensitivity to FSH, which may be
indirectly measured using markers of ovarian reserve
and sensitivity, namely AFC and serum day 3 FSH. The
prediction of ovarian response to maximal stimulation is
the basis for the modulation of the dose of FSH to ad-
minister to patients undergoing IVF. By modulating the
FSH starting dose, clinicians may increase the number
of patients with a satisfactory oocyte yield while redu-
cing both the extremes. Of course the validation of the
proposed FSH dosage nomogram in a large prospective
study is needed.
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